Molecular Neurodegeneration

(The TQCC of Molecular Neurodegeneration is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)
The neuropathological diagnosis of Alzheimer’s disease929
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles188
Dementia with Lewy bodies: an update and outlook144
Glucocerebrosidase and its relevance to Parkinson disease141
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology135
α-synuclein in the pathophysiology of Alzheimer’s disease131
Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease115
Neuroimaging Biomarkers for Alzheimer’s Disease113
Impaired dopamine metabolism in Parkinson’s disease pathogenesis110
Glucose transporter 1 critically controls microglial activation through facilitating glycolysis101
Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors101
Dural lymphatics regulate clearance of extracellular tau from the CNS95
Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease91
Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy85
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease83
Glial phagocytic clearance in Parkinson’s disease82
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same80
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease74